{"entity":{"id":"kopra-bio","kind":"company","name":"Kopra Bio","aka":[],"tldr":"Kopra Bio engineers viruses that teach the immune system to kill cancer, starting with glioblastoma, the most aggressive brain cancer.","summary":"Kopra Bio, a UCSF spin-out, develops genetically engineered immunotherapeutic viruses designed to prime the immune system against tumours, with glioblastoma as the first indication. Its YC profile reports that in an aggressive mouse model of brain cancer the treatment raised survival from zero with the current approved therapy to 90 percent, a preclinical result that has not yet been tested in patients. The company is very small and preclinical; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/kopra-bio"},{"label":"Official website","url":"https://kopra.bio"}],"tags":["yc"],"related":[],"cancers":["glioblastoma"],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://kopra.bio","stage":"startup","ycBatch":"S24","investors":["y-combinator"],"funding":[]},"route":"/companies/kopra-bio/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}